Why I no longer accept pens (or other "gifts") from industry (and why you shouldn't either)

Journal of Rheumatology

Volumn 31, Issue 8, 2004, Pages 1478-1482

  Panush, Richard S ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; ATTITUDE; BEHAVIOR; CAREER; CLINICAL PRACTICE; CURRICULUM; DRUG INDUSTRY; DRUG MARKETING; EDITORIAL; ETHICS; GIFT GIVING; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL PRACTICE; MEDICAL PROFESSION; MOTIVATION; PERCEPTION; PHYSICIAN; PRIORITY JOURNAL; RHEUMATOLOGY;

HEALTH CARE AND PUBLIC HEALTH;

CONFLICT OF INTEREST; DRUG INDUSTRY; GIFT GIVING; HUMANS; PHYSICIANS;

EID: 3442898463     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Opren scandal [editorial]. Lancet 1983;1:219-20.
2. Rawlins MD. Doctors and the drug makers. Lancet 1984;2:276-8.
3. Pellegrino ED, Relman AS. Professional medical associations. Ethical and practical guidelines. JAMA 1999;282:984-6.
4. Panush RS. Introduction to miscellaneous topics. In: Panush RS, editor. Yearbook of rheumatology, arthritis, and musculoskeletal diseases. St. Louis: Mosby; 2001:349-59.
5. Panush RS. Not for sale, not even for rent: just say no. Thoughts about The American College of Rheumatology adopting a code of ethics. J Rheumatol 2002;29:1049-57.
6. Panush RS. [Reply to letter]. J Rheumatol 2003;30:202-3.
7. Panush RS. Professionalism-it's all about the patient. And respect. Rounds. Saint Barnabas Health Care System. Winter 2003:1-2.
8. Panush RS, Kavanaugh A, Romain P. Ethical issues in rheumatologic practice and investigation. In: Smolen JS, Lipsky PE, editors. Biological therapy in rheumatology. London: Martin Dunitz Publishers; 2003:639-51.
9. Dendi P, Desai S, Jacobs FM, et al. Why ethics are important to the busy practitioner caring for patients with rheumatologic and musculoskeletal disorders. Bull Rheum Dis 2003:52:1-7.
10. Panush RS, Sergent JS. A rude awakening. JAMA 1997;277:515-6.
11. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA 2001;285:2009-12.
12. Hadler NM. Hubris for sale or rent. Rheuma21st Archived Reports [Internet]. 1999 [cited April 5, 2004]. Available from: http://www.rheuma21st. com/archives/ACR99.html
13. Angell M. Is academic medicine for sale? N Engl J Med 2000;342:1516-8.
14. Kassirer JP. Financial indigestion. JAMA 2000;284:2156-7.
15. Korn D. Conflicts of interest in biomedical research. JAMA 2000;284:2234-6.
16. DeAngelis CD. Conflict of interest and the public trust. JAMA 2000;284:2237-8.
17. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5.
18. Carrasquillo O, Goodman RL. Pharma's bad karma. Resistance is not futile. J Gen Intern Med 2003;18:315-6.
19. Time to untangle doctors from drug companies [theme issue]. BMJ 2003;346:1155-210.
20. Just how tainted has medicine become? [editorial]. Lancet 2002;59:1167.
21. Drug-company influence on medical education in USA [editorial]. Lancet 2000;356:781.
22. Relman A. Your doctor's drug problem. New York Times 2003; Nov 18.
23. Stobo JD, Cohen JJ, Kimball HR, LaCombe MA, Schechter GP. Blank LL. Project professionalism. Philadelphia: American Board of Internal Medicine; 1995:1-29.